Abstract
We selected four patients with severe Gilles de la Tourette syndrome, high frequency of tics (two to ten per minute), vocalizations, and lack of comorbidity. These patients (aged 19–40 years) underwent a 52-week double-blind cross-over study with olanzapine (5 and 10 mg daily) vs. low-dose pimozide (2 and 4 mg daily). The reduction in rating scale scores for the syndrome was highly significant with 10 mg olanzapine vs. basal and vs. 2 mg pimozide, and was significant for 5 mg olanzapine vs. 4 mg pimozide. Only moderate sedation was reported by one patient during olanzapine treatment while three complained of minor motor side effects and sedation during pimozide treatment. At the end of the study all patients opted for olanzapine treatment.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 23 July 1999, Received in revised form: 30 November 1999, Accepted: 22 January 2000
Rights and permissions
About this article
Cite this article
Onofrj, M., Paci, C., D'Andreamatteo, G. et al. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 247, 443–446 (2000). https://doi.org/10.1007/s004150070173
Issue Date:
DOI: https://doi.org/10.1007/s004150070173